PLoS ONE · 2014 · 26 citations · 41 references
MedicineGeneticsOncologyMetastasisMolecular OncologyTumor ProgressionCancer GenomicsCancer ImmunotherapyCancer ProgressionCancer Survival AnalysisHer2-positive Breast CancerMetastatic Breast CancerBreast Cancer ProgressionBreast Cancer Resistance MechanismsDurable Clinical ResponseHer2-positive Metastatic DiseaseMetastatic Breast Cancer TreatmentMetastatic Her2-positive Breast CancerMolecular Prognostic MarkersTrastuzumab Resistance
BACKGROUND: Trastuzumab improves survival outcomes in patients with HER2+ metastatic breast cancer. The Long-Her study was designed to identify clinical and molecular markers that could differentiate long-term survivors from patients having early progression after trastuzumab treatment. METHODS: Data were collected from women with HER2-positive metastatic breast cancer treated with trastuzumab that experienced a response or stable disease during at least 3 years. Patients having a progression in the first year of therapy with trastuzumab were used as a control. Genes related with trastuzumab resistance were identified and investigated for network and gene functional interrelation. Models predicting poor response to trastuzumab were constructed and evaluated. Finally, a mutational status analysis of selected genes was performed in HER2 positive breast cancer samples. RESULTS: 103 patients were registered in the Long-HER study, of whom 71 had obtained a durable complete response. Median age was 58 years. Metastatic disease was diagnosed after a median of 24.7 months since primary diagnosis. Metastases were present in the liver (25%), lungs (25%), bones (23%) and soft tissues (23%), with 20% of patients having multiple locations of metastases. Median duration of response was 55 months. The molecular analysis included 35 patients from the group with complete response and 18 patients in a control poor-response group. Absence of trastuzumab as part of adjuvant therapy was the only clinical factor associated with long-term survival. Gene ontology analysis demonstrated that PI3K pathway was associated with poor response to trastuzumab-based therapy: tumours in the control group usually had four or five alterations in this pathway, whereas tumours in the Long-HER group had two alterations at most. CONCLUSIONS: Trastuzumab may provide a substantial long-term survival benefit in a selected group of patients. Whole genome expression analysis comparing long-term survivors vs. a control group predicted early progression after trastuzumab-based therapy. Multiple alterations in genes related to the PI3K-mTOR pathway seem to be required to confer resistance to this therapy.
41
In silico prediction of protein-protein interactions in human macrophages
Oussema Souiai, Fatma Z. Guerfali, Slimane Ben Miled et al. · BMC Research Notes · 2014 · 11K citations · Full text
TM4: A Free, Open-Source System for Microarray Data Management and Analysis
A Saeed, Vasily Sharov, Joseph White et al. · BioTechniques · 2003 · 5K citations · Full text
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Ken Inoki, Tianqing Zhu, Kun‐Liang Guan · Cell · 2003 · 3.9K citations · Full text